Department of Thoracic-Cardiac Surgery, The Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, 107 Yanjiangxi Rd., Guangzhou 510120, PR China.
Lung Cancer. 2012 Apr;76(1):106-11. doi: 10.1016/j.lungcan.2011.09.005. Epub 2011 Oct 7.
Methylation of human tissue factor pathway inhibitor-2 (TFPI-2) gene has been detected in several types of cancer, including non-small cell lung cancer (NSCLC). However, an association between the methylation status of TFPI-2 gene and prognosis has not yet been investigated.
Methylation of TFPI-2 gene was examined in a consecutive series of 133 non-metastatic NSCLC patients using methylation-specific PCR (MSP). Univariate and multivariate analyses were conducted to investigate the association between clinical variables and overall survival time.
Methylation of TFPI-2 gene was detected in 36 of 133 patients (27.1%). Of these 36 patients, seventeen individuals (47.2%) carried stage III tumors. The 5-year disease free survival rate among patients carrying methylated TFPI-2 tumors was significantly lower as compared to those with unmethylated TFPI-2 tumors (35.5% versus 6.1%, P<0.0001). Moreover, methylation of TFPI-2 gene was found to be an independent prognostic factor for poor overall survival based on multivariate analysis models (P=0.013), as was age >62 years old (P<0.0001) and TNM stage of disease (P<0.0001).
The results of the present study suggest that methylation of TFPI-2 gene is an independent factor for an unfavorable prognosis in patients with NSCLC.
人类组织因子途径抑制物-2（TFPI-2）基因的甲基化已在多种类型的癌症中被检测到，包括非小细胞肺癌（NSCLC）。然而，TFPI-2 基因甲基化状态与预后之间的关联尚未得到研究。
采用甲基化特异性 PCR（MSP）检测 133 例非转移性 NSCLC 患者连续系列中 TFPI-2 基因的甲基化情况。采用单因素和多因素分析来研究临床变量与总生存时间之间的关系。
在 133 例患者中，有 36 例（27.1%）检测到 TFPI-2 基因的甲基化。在这 36 例患者中，17 例（47.2%）患者为 III 期肿瘤。携带甲基化 TFPI-2 肿瘤的患者 5 年无病生存率明显低于未携带甲基化 TFPI-2 肿瘤的患者（35.5%比 6.1%，P<0.0001）。此外，基于多因素分析模型，TFPI-2 基因的甲基化被发现是总生存不良的独立预后因素（P=0.013），年龄>62 岁（P<0.0001）和疾病的 TNM 分期（P<0.0001）也是独立预后因素。
本研究结果表明，TFPI-2 基因甲基化是非小细胞肺癌患者预后不良的独立因素。
